| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 17.68 mm | 17.68 mm | 17.68 mm | 17.68 mm | 17.68 mm | 17.68 mm |
| Cash burn (monthly) | 1.42 mm | (no burn) | 2.02 mm | 2.47 mm | 1.27 mm | 2.32 mm |
| Cash used (since last report) | 6.07 mm | n/a | 8.64 mm | 10.53 mm | 5.44 mm | 9.92 mm |
| Cash remaining | 11.61 mm | n/a | 9.04 mm | 7.14 mm | 12.24 mm | 7.76 mm |
| Runway (months of cash) | 8.2 | n/a | 4.5 | 2.9 | 9.6 | 3.3 |
| 13F holders | Current |
|---|---|
| Total holders | 23 |
| Opened positions | 7 |
| Closed positions | 13 |
| Increased positions | 3 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 9.75 bn |
| Total shares | 4.19 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| University Of Texas/texas Am Investment Managment | 1.40 mm | $4.97 bn |
| Novartis Bioventures | 1.20 mm | $765.00 k |
| Vanguard | 432.20 k | $1.53 bn |
| Biotechnology Value Fund L P | 236.84 k | $0.00 |
| Senvest Management | 230.90 k | $801.02 mm |
| Geode Capital Management | 229.82 k | $813.77 mm |
| Sigma Planning | 212.41 k | $751.93 mm |
| Gagnon Securities | 71.76 k | $254.03 mm |
| BlackRock | 51.28 k | $181.53 mm |
| NTRS Northern Trust | 25.76 k | $91.20 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Dec 24 | James Brian Windsor | Common Stock | Buy | Acquire P | Yes | No | 2.25 | 161 | 362.25 | 161 |
| 5 Dec 24 | James Brian Windsor | Common Stock | Buy | Acquire P | Yes | No | 2.24 | 239 | 535.36 | 239 |
| 2 Dec 24 | James Brian Windsor | Stock Option Common Stock | Grant | Acquire A | No | No | 2.85 | 517,500 | 1.47 mm | 517,500 |
| 2 Dec 24 | Alan A Musso | Stock Option Common Stock | Grant | Acquire A | No | No | 2.85 | 35,000 | 99.75 k | 35,000 |
| 2 Dec 24 | William Fairey | Stock Option Common Stock | Grant | Acquire A | No | No | 2.85 | 35,000 | 99.75 k | 35,000 |
| 2 Dec 24 | Von Rickenbach Josef H | Stock Option Common Stock | Grant | Acquire A | No | No | 2.85 | 35,000 | 99.75 k | 35,000 |
